4D Molecular Therapeutics’ (FDMT) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a research report released on Thursday morning,Benzinga reports. Chardan Capital currently has a $26.00 price target on the stock.

Several other equities research analysts have also issued reports on FDMT. Royal Bank Of Canada reissued an “outperform” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, January 7th. Wall Street Zen lowered shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Barclays began coverage on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $33.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 21st. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $32.17.

4D Molecular Therapeutics Trading Up 4.9%

Shares of NASDAQ:FDMT opened at $8.98 on Thursday. The firm has a market capitalization of $513.03 million, a PE ratio of -3.71 and a beta of 2.99. 4D Molecular Therapeutics has a 1-year low of $2.23 and a 1-year high of $12.34. The business’s 50 day moving average is $8.73 and its 200-day moving average is $9.08.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Wednesday, March 18th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.96. The business had revenue of $85.09 million during the quarter, compared to analyst estimates of $30.86 million. 4D Molecular Therapeutics had a negative return on equity of 33.37% and a negative net margin of 164.43%. On average, sell-side analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

Institutional Trading of 4D Molecular Therapeutics

Large investors have recently added to or reduced their stakes in the company. BVF Inc. IL raised its stake in shares of 4D Molecular Therapeutics by 1.5% in the second quarter. BVF Inc. IL now owns 4,629,289 shares of the company’s stock valued at $17,175,000 after acquiring an additional 68,000 shares during the last quarter. XTX Topco Ltd bought a new stake in 4D Molecular Therapeutics during the 2nd quarter worth approximately $292,000. Dynamic Technology Lab Private Ltd grew its position in 4D Molecular Therapeutics by 35.6% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 16,369 shares of the company’s stock worth $61,000 after acquiring an additional 4,295 shares during the last quarter. SG Americas Securities LLC acquired a new stake in 4D Molecular Therapeutics during the 4th quarter valued at $116,000. Finally, Harbor Capital Advisors Inc. increased its holdings in 4D Molecular Therapeutics by 149.7% during the 4th quarter. Harbor Capital Advisors Inc. now owns 29,716 shares of the company’s stock valued at $223,000 after purchasing an additional 17,815 shares in the last quarter. 99.27% of the stock is owned by institutional investors.

Key Stories Impacting 4D Molecular Therapeutics

Here are the key news stories impacting 4D Molecular Therapeutics this week:

• Positive Sentiment: Q4 earnings and revenue materially beat expectations — reported EPS $0.43 vs. consensus ~($0.53) and revenue $85.09M vs. $30.86M expected, signaling stronger commercial performance than feared. Zacks: Q4 Results
• Positive Sentiment: Royal Bank of Canada raised its price target to $35 and assigned an “outperform” rating, providing a high upside thesis that can attract momentum buyers. Benzinga: RBC PT Raise
• Positive Sentiment: Chardan Capital reaffirmed a “buy” rating and set a $26 price target, reinforcing analyst support for the shares. Benzinga: Chardan Reaffirmation
• Positive Sentiment: Company press release outlining full‑year 2025 financial results, operational highlights and expected upcoming milestones provides an updated roadmap that may support continued upside if clinical/commercial milestones are achieved. GlobeNewswire: FY2025 Results & Milestones
• Neutral Sentiment: Short‑interest notices in mid‑March show anomalous/zero reported short shares (entries list 0 shares and NaN changes), which is ambiguous and unlikely to be driving meaningful short‑squeeze dynamics at this time.
• Negative Sentiment: Despite the beat, underlying metrics remain mixed: 4DMT reported a very large negative net margin and negative return on equity, and some analysts still expect negative full‑year EPS. These fundamentals keep valuation and profitability risks on the table. Press Release / Financials

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.